Who are artificial tear therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Preservative-free artificial tears, Non-Lipid Artificial Tear, Arificial Tear, Systane PRO, Hyaluronic acid 0.05% & Ectoine 2.0%, Rohto (r) Hydra.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/artificial-tear-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

artificial tear therapy — Competitive Intelligence Brief

artificial tear therapy (artificial tear therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ophthalmic lubricant. Area: Ophthalmology.

marketed Ophthalmic lubricant Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

artificial tear therapy (artificial tear therapy) — Tianjin Medical University Eye Hospital. Artificial tear therapy replaces or supplements the eye's natural tear film to lubricate the ocular surface and relieve symptoms of dry eye disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
artificial tear therapy TARGET	artificial tear therapy	Tianjin Medical University Eye Hospital	marketed	Ophthalmic lubricant
Preservative-free artificial tears	Preservative-free artificial tears	University Hospital, Ghent	marketed	Ophthalmic lubricant
Non-Lipid Artificial Tear	Non-Lipid Artificial Tear	University of Seville	marketed	Artificial tear / Ophthalmic lubricant
Arificial Tear	Arificial Tear	Massachusetts Eye and Ear Infirmary	marketed	Ophthalmic lubricant
Systane PRO	Systane PRO	Scripps Poway Eyecare and Optometry	marketed	Ophthalmic lubricant / artificial tear
Hyaluronic acid 0.05% & Ectoine 2.0%	Hyaluronic acid 0.05% & Ectoine 2.0%	Michael Marchand, MD	marketed	Ophthalmic lubricant and protectant
Rohto (r) Hydra	Rohto (r) Hydra	ORA, Inc.	marketed	Ophthalmic lubricant / Artificial tear

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ophthalmic lubricant class)

Allergan · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Massachusetts Eye and Ear Infirmary · 1 drug in this class
National University of Malaysia · 1 drug in this class
Nguyen Viet Giap · 1 drug in this class
Ophthalmic Consultants of Long Island · 1 drug in this class
Tianjin Medical University Eye Hospital · 1 drug in this class
Universidad Nacional de Colombia · 1 drug in this class
University Hospital, Ghent · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). artificial tear therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/artificial-tear-therapy. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab